BC Week In Review | Dec 2, 2016
Clinical News

ASN-002: Interim Ph I/IIa data

Interim data from 9 patients with nodular BCC in an open-label, Australian Phase I/IIa trial showed that once-weekly intratumoral ASN-002 for 3 weeks led to an overall response rate (ORR) of 100%, comprising 67% complete...
BC Week In Review | Oct 19, 2015
Clinical News

TG1042: Phase I/II started

Ascend began an open-label, Australian Phase I/II trial to evaluate weekly intratumoral injections of ASN-002 in up to 36 patients prior to surgical tumor excision. Patients will receive ASN-002 for 3 weeks or for 7...
BC Week In Review | Jul 15, 2013
Company News

Ascend Biopharmaceuticals, Transgene deal

Transgene granted Ascend rights to develop and commercialize TG1042 ( ASN-002 ) to treat basal cell carcinoma, bladder cancer and an additional indication to be selected by Ascend. Transgene retains rights to other potential indications. Ascend plans...
BC Week In Review | Dec 8, 2008
Clinical News

TG1042: Interim Phase II data

Interim data from 12 evaluable patients in the first part of an open-label, U.S. and European Phase II trial, showed that TG1042 produced 5 complete responses, 5 partial responses and 2 cases of stable disease....
BioCentury | Apr 7, 2008

2Q Financial Markets Preview: Longing for normalcy

With stock market volatility expected to continue this quarter, investors say they will continue the flight to quality that began at the end of last year. The few buysiders who are not sitting on the...
BC Week In Review | Mar 19, 2007
Clinical News

TG1042: Phase II started

Transgene started an open-label, U.S. and European Phase II trial in 41 patients with relapsing CBCL. The first part of the trial will enroll 13 patients, while the second part will enroll 28 patients, all...
BC Week In Review | Oct 16, 2006
Clinical News

Ad-IFNg: Phase II/III start

Next month, Transgene will begin a Phase II/III trial. Transgene S.A. (Euronext:Transgene), Strasbourg, France   Product: Ad-IFNg ( TG1042 )   Business: Cancer   Molecular target: Not applicable   Description: Adenoviral vector encoding interferon gamma gene  ...
BC Extra | Jul 25, 2006
Financial News

Transgene raises EUR 14.3 million

Transgene (Euronext:Transgene) raised EUR 14.3 million ($18.2 million) through the conversion 3.6 million of the 4.7 million warrants issued in its July 2005 follow-on. The warrants converted into 1.8 million shares at a strike price...
BioCentury | Jul 10, 2006

Transgene's nail biter

Therapeutic vaccine company Transgene S.A. will know by this Friday whether it will get a cash bolus representing about a year of cash or if it will have to go out on the road to...
BioCentury | May 29, 2006
Product Development

ASCO presenters

ASCO presenters Company Product Presentation title Accentia BiovaxID Idiotype vaccine therapy of follicular lymphoma in first remission: Association of t(14;18) and disease free survival in a phase II cohort Antigenics Oncophage vitespen Autologous tumor-derived HSPPC-96...
Items per page:
1 - 10 of 24